Trametinib
Trametinib is an orally active, ATP-noncompetitive inhibitor of MEK1 and MEK2 (IC50=0.7/0.9 nM) . It is widely used in cancer research to study pathways involving cell proliferation and survival, as it can induce autophagy and apoptosis in both in vitro and in vivo models.
Product Specifications
CAS Number
871700-17-3
Product Name Alternative
GSK1120212; JTP-74057
Field of Research
Cell Biology, Pharmacology & Drug Discovery, Signal Transduction
Purity
>98%
Bioactivity
MEK inhibitor
Form
Powder
Solubility
Soluble in DMSO (up to 20 mg/ml with warming)
Smiles
N (C1=C2C (N (C (=O) N (C2=O) C3CC3) C4=CC (NC (C) =O) =CC=C4) =C (C) C (=O) N1C) C5=C (F) C=C (I) C=C5
Molecular Formula
C26H23FIN5O4
Molecular Weight
615.4
Storage Conditions
-20°C
Notes
For research use only.
Other Product Names
N-{3-[3-Cyclopropyl-5- (2-fluoro-4-iodophenylamino) -6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Total RNA - Human Adult Normal Tissue 5 Donor Pool: Adrenal
Recombinant Mycobacterium tuberculosis Uncharacterized protein Rv2265/MT2327 (Rv2265, MT2327), partial
Recombinant Mycobacterium tuberculosis Uncharacterized protein Rv2265/MT2327 (Rv2265, MT2327), partial
RASSF5 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)